<code id='570825B509'></code><style id='570825B509'></style>
      • <acronym id='570825B509'></acronym>
      <center id='570825B509'><center id='570825B509'><tfoot id='570825B509'></tfoot></center><abbr id='570825B509'><dir id='570825B509'><tfoot id='570825B509'></tfoot><noframes id='570825B509'>
      • <optgroup id='570825B509'><strike id='570825B509'><sup id='570825B509'></sup></strike><code id='570825B509'></code></optgroup>
        5. <b id='570825B509'><label id='570825B509'><select id='570825B509'><dt id='570825B509'><span id='570825B509'></span></dt></select></label></b><u id='570825B509'></u>
          <i id='570825B509'><strike id='570825B509'><tt id='570825B509'><pre id='570825B509'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / comprehensive / leisure time      
           
     
           
      
          leisure time 
           
      
           
      
           
       2025-09-29 08:53:55 
   
      
           
      
           
                        
          leisure time  
          
                                   
                 
                                      author：comprehensive   
                                        
                                      
                                      Page View：25247
                                  
                                    
          
                                   
          translucent 3D DNA helix with blue and purple background
          Adobe
          Verve Therapeutics said Monday that it had received clearance from the Food and Drug Administration to conduct a clinical trial in the U.S. of its experimental, gene-editing treatment for a common form of heart disease.
          The FDA’s action removes a clinical hold on Verve’s CRISPR-based therapy, called VERVE-101, that was placed on it last November. Verve now intends to recruit participants from U.S. sites into a Phase 1 study that’s been underway since last year in New Zealand and the United Kingdom.
          advertisement
          “We’re thrilled to get this clearance for VERVE-101,” said Verve CEO Sek Kathiresan. “Our study is called HEART-1 and our plan now is to activate U.S. sites.”
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe													Log In											
                      
                              
          
                                 Previous article：

                                
                                          STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list
                                
                            
          Next article：  
                                      
                                          Medicare proposal to cover medical devices draws a mixed reaction
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles